Faculty Profiles - SONE, Hirohito

Papers - SONE, Hirohito

Division display 321 - 340 of about 618 ／ All the affair displays >>

耐糖能及び肥満の有無別にみた代謝異常が冠動脈疾患発症に及ぼす影響の検討 Reviewed

藤原和哉, 松林泰弘, 山本正彦, 金子正儀, 松永佐澄志, 山田貴穂, 清田浩康, 山中菜詩, 児玉暁, 曽根博仁

日本動脈硬化学会総会プログラム・抄録集 50回 336 - 336 2018.6

眼科処置を要する重症糖尿病性眼疾患の発生リスクに対する腎症の影響についての検討 Reviewed

山本正彦, 藤原和哉, 大澤妙子, 原田万祐子, 石黒創, 石澤正博, 岩永みどり, 松永佐澄志, 松林泰弘, 清田浩康, 山中菜詩, 山田貴穂, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 161 2018.4

日本人2型糖尿病患者における、ビタミンB6摂取量と糖尿病網膜症発症との関係 JDCSによる報告 Reviewed

堀川千嘉, 相田麗, 田中司朗, 鎌田智恵実, 田中佐智子, 吉村幸雄, 川崎良, 山下英俊, 大橋靖雄, 井藤英喜, 赤沼安夫, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 141 2018.4

2型糖尿病患者における食事エネルギー密度と肥満との関連 JDDMにおける検討 Reviewed

武田安永, 藤原和哉, 治田麻理子, 森川咲子, 堀川千嘉, 石井大, 加藤光敏, 横山宏樹, 栗原義夫, 宮澤一裕, 岩崎晧一, 川井紘一, 朝長修, 屋宜宣治, 前川聡, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 265 2018.4

肥満境界型糖尿病患者に対する血糖自己測定と栄養指導媒体を用いた栄養教育の併用効果について Reviewed

長谷川美代, 堀川千嘉, 田代稔, 鈴木沙織, 藤原和哉, 北澤勝, 加藤公則, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 267 2018.4

指先穿刺による血糖およびHbA1c迅速測定をもちいた糖尿病啓発の取り組み Reviewed

山田貴穂, 石井大, 武田安永, 橋本浩平, 三ツ間友里恵, 張かおり, 原田万祐子, 白石友信, 吉岡大志, 山本正彦, 大澤妙子, 石黒創, 金子正儀, 鈴木浩史, 松林泰弘, 松永佐澄志, 藤原和哉, 岩永みどり, 鈴木亜希子, 羽入修, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 377 2018.4

糖尿病患者における脈圧が透析導入に及ぼす影響の検討 Reviewed

大澤妙子, 藤原和哉, 山本正彦, 原田万由子, 石澤正博, 清田浩康, 山中菜詩, 松林泰弘, 松永佐澄志, 山田貴穂, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 160 2018.4

診断に難渋した再発性重症低血糖の原因特定に薬物血中濃度測定が有用であった一例 Reviewed

三ツ間友里恵, 山本正彦, 橋本浩平, 金子正儀, 松林泰弘, 松永佐澄志, 山田貴穂, 岩永みどり, 藤原和哉, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 181 2018.4

糖尿病治療薬別にみたHbA1cと冠動脈疾患(CAD)発症リスクとの関連 Reviewed

原田万祐子, 藤原和哉, 大澤妙子, 石澤正博, 山本正彦, 金子正儀, 松林泰弘, 松永佐澄志, 山中菜詩, 清田浩康, 山田貴穂, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 258 2018.4

耐糖能及び肥満の有無に関わらず代謝異常は冠動脈疾患発症リスクを増大させる Reviewed

藤原和哉, 松林泰弘, 山本正彦, 松永佐澄志, 清田浩康, 山中菜詩, 児玉暁, 曽根博仁

糖尿病 61 ( Suppl.1 ) S - 260 2018.4

Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. Reviewed

Kazuya Fujihara, Hirohito Sone

Annals of vascular diseases 11 ( 1 ) 2 - 14 2018.3

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal)

Individuals with diabetes have a two- to four-fold increased risk of coronary artery disease (CAD) and higher mortality rates than those without diabetes. Because not only microvascular but also macrovascular disease in patients with diabetes are known to predispose patients to a lower quality of life as well as lead to higher mortality rates, identifying and managing risk factors of CAD is of clinical relevance in diabetes care. A number of antihyperglycemic drugs are currently approved for the treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM), with several new drugs having been developed during the last decade. Diabetes-related complications have been substantially reduced worldwide. However, in view of the current situation in which both the prevalence of obesity and glucose abnormality have increased worldwide, including Japan, diet and exercise remain the crucial means of treatment for patients with diabetes. Furthermore, predicting the development of CAD is essential. This review summarizes data from recent studies on cardiovascular disease in patients with T2DM, focusing on clinical trials and big data, including studies involving Japanese individuals.

DOI： 10.3400/avd.ra.17-00109

PubMed

researchmap

Predictors of the response of HbA1c and body weight after SGLT2 inhibition. Reviewed International journal

T Abe, Y Matsubayashi, A Yoshida, H Suganami, T Nojima, T Osawa, M Ishizawa, M Yamamoto, K Fujihara, S Tanaka, K Kaku, H Sone

Diabetes & metabolism 44 ( 2 ) 172 - 174 2018.3

Role of fatty liver in the association between obesity and reduced hepatic insulin clearance. Reviewed International journal

Y Matsubayashi, A Yoshida, H Suganami, H Ishiguro, M Yamamoto, K Fujihara, S Kodama, S Tanaka, K Kaku, H Sone

Diabetes & metabolism 44 ( 2 ) 135 - 142 2018.3

Authorship：Corresponding author Language：English

AIM: Hepatic insulin clearance (HIC) is important in regulating plasma insulin levels. Diminished HIC causes inappropriate hyperinsulinaemia, and both obesity and fatty liver (FL), which are known to decrease HIC, can be found either together in the same patient or on their own. The mechanism by which obesity reduces HIC is presumed to be mediated by FL. However, few reports have examined the role of FL in the relationship between obesity and HIC in type 2 diabetes (T2D) patients. Therefore, our study investigated the association of HIC with clinical factors, including insulin sensitivity indices, focusing on the presence or absence of FL and obesity in T2D patients. METHOD: Baseline data from 419 patients with T2D (279 men, 140 women; mean age: 57.6 years; body mass index: 25.5kg/m2) controlled by diet and exercise were analyzed. HIC was calculated from the ratio of fasting c-peptide to fasting insulin levels (HICCIR). Correlation analyses between HICCIR and clinical variables were performed using Pearson's product-moment correlation coefficients and single regression analysis in all participants and in those with obesity and FL either alone or in combination. RESULTS: HICCIR was significantly correlated with whole-body insulin sensitivity indices and influenced by FL, but only in the FL group was obesity independently influenced HIC level. HICCIR decreased in those with both FL and obesity compared with those with only one such complication. CONCLUSION: HICCIR may be used to evaluate whole-body insulin sensitivity in T2D. Also, compared with obesity, the influence of FL strongly contributed to a reduced HIC. TRIAL REGISTRATION NUMBER: These trials were registered by the Japan Pharmaceutical Information Centre clinical trials information (JapicCTI) as 101349 and 101351.

DOI： 10.1016/j.diabet.2017.12.003

PubMed

researchmap

MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia. Reviewed

Takashi Kozakai, Masahiko Takahashi, Masaya Higuchi, Toshifumi Hara, Kousuke Saito, Yuetsu Tanaka, Masayoshi Masuko, Jun Takizawa, Hirohito Sone, Masahiro Fujii

International journal of hematology 107 ( 3 ) 337 - 344 2018.3

Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Tokyo

Membrane-associated guanylate kinase with inverted orientation protein 1 (MAGI-1) is a cytoplasmic scaffold protein that interacts with various signaling molecules; it negatively controls the cell growth of various types of cells and positively controls cell-cell interaction. In T cells, MAGI-1 has been shown to inhibit Akt activity through its interaction with PTEN and MEK1. In this study we found that MAGI-1 expression is decreased in multiple (9 out of 15) human T-cell leukemia cell lines, including adult T-cell leukemia (ATL), T-cell acute lymphoblastic leukemia and chronic T-cell lymphocytic leukemia. The overexpression of MAGI-1 protein in a MAGI-1-low ATL cell line reduced cellular growth. While the overexpression of MAGI-1 protein in a MAGI-1-low ATL cell line reduced the Akt and MEK activities, the knockdown of MAGI-1 in a MAGI-1-high ATL cell line augmented the Akt and MEK activities. Collectively, the findings of the present study suggest that the decreased expression of MAGI-1 in human T cells contributes to the development of several types of T-cell leukemia, partly through the stimulation of the Akt and MEK pathways.

DOI： 10.1007/s12185-017-2359-1

Scopus

PubMed

researchmap

Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. Reviewed International journal

Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa

Hematological oncology 36 ( 1 ) 166 - 173 2018.2

Language：English Publishing type：Research paper (scientific journal)

Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma with a poor prognosis. Although first-line treatments for patients with localized ENKTL have been established, there is no gold standard treatment for patients with advanced ENKTL and refractory and/or relapsed disease. Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression. In particular, this therapeutic agent has recently been suggested to be effective for Hodgkin lymphoma and mature T-cell lymphoma. However, the efficacy of BV toward ENKTL has not yet been established. Therefore, we investigated the expression of CD30 in a large cohort to evaluate BV as a potential treatment for ENKTL. In this study, 97 Japanese patients with newly diagnosed ENKTL between January 2007 and December 2015 were enrolled. Flow cytometry and immunohistochemistry were performed for the evaluation of CD30 expression. If the cut-off value of CD30 expression is 1% or more, there were 55 positive cases (56.5%). According to the localization of lesion, the frequency of CD30 expression was significantly higher in the non-nasal type than in the nasal type (P = .0394). No differences were observed in almost all clinical characteristics between CD30-positive cases and CD30-negative cases. In addition, the expression of CD30 was not a prognostic factor for either overall survival or progression-free survival. In conclusion, frequent expression of CD30 in ENKTL suggests anti-CD30 antibody-based therapy may be an effective treatment.

DOI： 10.1002/hon.2482

PubMed

researchmap

Quantitative Relationship Between Cumulative Risk Alleles Based on Genome-Wide Association Studies and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Reviewed

Satoru Kodama, Kazuya Fujihara, Hajime Ishiguro, Chika Horikawa, Nobumasa Ohara, Yoko Yachi, Shiro Tanaka, Hitoshi Shimano, Kiminori Kato, Osamu Hanyu, Hirohito Sone

Journal of epidemiology 28 ( 1 ) 3 - 18 2018.1

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal)

Many epidemiological studies have assessed the genetic risk of having undiagnosed or of developing type 2 diabetes mellitus (T2DM) using several single nucleotide polymorphisms (SNPs) based on findings of genome-wide association studies (GWAS). However, the quantitative association of cumulative risk alleles (RAs) of such SNPs with T2DM risk has been unclear. The aim of this meta-analysis is to review the strength of the association between cumulative RAs and T2DM risk. Systematic literature searches were conducted for cross-sectional or longitudinal studies that examined odds ratios (ORs) for T2DM in relation to genetic profiles. Logarithm of the estimated OR (log OR) of T2DM for 1 increment in RAs carried (1-ΔRA) in each study was pooled using a random-effects model. There were 46 eligible studies that included 74,880 cases among 249,365 participants. In 32 studies with a cross-sectional design, the pooled OR for T2DM morbidity for 1-ΔRA was 1.16 (95% confidence interval [CI], 1.13-1.19). In 15 studies that had a longitudinal design, the OR for incident T2DM was 1.10 (95% CI, 1.08-1.13). There was large heterogeneity in the magnitude of log OR (P < 0.001 for both cross-sectional studies and longitudinal studies). The top 10 commonly used genes significantly explained the variance in the log OR (P = 0.04 for cross-sectional studies; P = 0.006 for longitudinal studies). The current meta-analysis indicated that carrying 1-ΔRA in T2DM-associated SNPs was associated with a modest risk of prevalent or incident T2DM, although the heterogeneity in the used genes among studies requires us to interpret the results with caution.

DOI： 10.2188/jea.JE20160151

PubMed

researchmap

Impact of Prior Coronary Artery Disease (CAD) and Glucose Tolerance Status (GTS) on Incident CAD in Japanese Men

Hirohito Sone

Diabetes 2018

Impact of Carbohydrate Intake on Obesity in Japanese Patients with Type 2 Diabetes-An Analysis of the JDCP Registry

Hirohito Sone

Diabetes 2018

Commercially available elisa kit detects factor viii inhibitory antibodies earlier than bethesda assay, in severe hemophilia a patient with joint pain

Hirohito Sone

International Journal of Laboratory Hematology 2018

Association between Serum Amylase Level and Incidence of Type 2 Diabetes

Hirohito Sone

Diabetes 2018

　 PREV - NEXT 　

<SONE, Hirohito>

Papers - SONE, Hirohito